Compare Novavax Inc (NVAX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Shell PLC — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Shell PLC trades at $100.18 (market cap $284.34B). The key difference: Shell PLC is far larger — about 156.2× Novavax Inc's market cap, and Shell PLC pays a 3.12% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Shell PLC for 90 Days on average.
| NVAX | SHEL | |
|---|---|---|
Market Cap | $1.82B | $284.34B |
Volume | 6,198,505 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $12.75 | $100.20 |
52-Week Low | $6.22 | $70.31 |
Typical Hold Time | 59 Days | 90 Days |
Enterprise Value | $1.39B | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Shell (SHEL) trades at $100.20, up 3.46% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive earnings surprises in recent quarters. Recent developments include the approval of LNG Canada Phase 2 expansion, doubling export capacity, and strategic portfolio optimization through asset sales. Financial metrics indicate solid profitability with 8.76% net income margin and attractive valuation at P/E of 11.08.
Shell presents a compelling investment case with strong LNG growth prospects and portfolio optimization driving future cash flows. However, declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and volatile energy prices pose execution risks. Analyst consensus remains bullish with $102.53 price target, though current RSI levels suggest potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
